iACT for Eating Disorders in Type 1 Diabetes
Primary Purpose
Type 1 Diabetes, Eating Disorders
Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
iACT
Usual Care
Sponsored by
About this trial
This is an interventional treatment trial for Type 1 Diabetes
Eligibility Criteria
Inclusion Criteria:
- 16-45 years of age
- Diagnosis of Type 1 diabetes
- Eating disorder characterized by binge eating and/or problematic weight control behaviors, including withholding insulin (Bulimia Nervosa, Binge Eating and Purging Disorder spectrum diagnoses)
- Independently manages diabetes (not reliant on a caregiver)
Exclusion Criteria:
- Current suicidal ideation or self-harming behavior
- Diagnosis of Avoidant Restrictive Food Intake Disorder or Anorexia Nervosa spectrum diagnoses
- Hypoglycemic unawareness as assessed by the Gold Method
- Current substance abuse disorder or current or past psychotic disorder
- NonEnglish speaking
Sites / Locations
- Duke UniversityRecruiting
- Brown University
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
iACT Experimental Intervention
Usual Care
Arm Description
Outcomes
Primary Outcome Measures
Change in glycemic control as indexed by continuous glucose monitoring (CGM)
CGM indices of time in range, frequency of Level 1 and 2 hyperglycemia and blood glucose variability
Change in glycemic control as indexed by hemoglobin A1c (HbA1c)
Glycated hemoglobin (percentage of red blood cells that are glycated providing an estimate of average blood glucose over 3 months)
Change in eating disorder symptoms as indexed by the Eating Disorder Examination Global score
Severity of eating and body image concerns, frequency of engagement in maladaptive eating and weight control behaviors. Global scores range from 0-6, with higher scores indicating greater symptom severity (worse outcome).
Change in eating disorder symptoms as indexed by the Diabetes Eating Problems Survey
Severity of eating and body image concerns, frequency of engagement in maladaptive eating and weight control behaviors, specifically in the context of diabetes. Scores range from 0-80, with higher scores indicating greater symptom severity (worse outcome).
Change in diabetes self-management as indexed by the Diabetes Self-Management Questionnaire
Engagement in activities necessary to manage diabetes, including checking blood sugar and administering insulin. Scores range from 0-10 with higher scores indicating better self-management.
Acceptability as measured by meeting the recruitment target for the study
recruitment of n=128
Feasibility as measured by participant attrition less than 20%
Less than n=26 individuals dropping out of treatment prematurely
Secondary Outcome Measures
Change in diabetes distress as indexed by the Type 1 - Diabetes Distress Scale
Feelings of stress or overwhelm with the burden of living with diabetes and diabetes management. Scores range from 1-6, with higher scores indicating greater distress (worse outcome)
Change in NIH PROMIS Scale - Depression
8 items assessing depressive affect, scored 1-5 and t-score normed (mean of 50, standard deviation of 10). Higher scores indicating greater symptoms (worse outcome).
Change in NIH PROMIS Scale - Anxiety
8 items assessing anxious affect, scored 1-5 and t-score normed (mean of 50, standard deviation of 10). Higher scores indicating greater symptoms (worse outcome).
Full Information
NCT ID
NCT05540704
First Posted
September 9, 2022
Last Updated
April 18, 2023
Sponsor
Duke University
Collaborators
The Miriam Hospital
1. Study Identification
Unique Protocol Identification Number
NCT05540704
Brief Title
iACT for Eating Disorders in Type 1 Diabetes
Official Title
A Randomized Controlled Trial of iACT, a Novel mHealth Intervention for Eating Disorders in Type 1 Diabetes
Study Type
Interventional
2. Study Status
Record Verification Date
April 2023
Overall Recruitment Status
Recruiting
Study Start Date
April 4, 2023 (Actual)
Primary Completion Date
June 1, 2026 (Anticipated)
Study Completion Date
June 1, 2026 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Duke University
Collaborators
The Miriam Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This project is a randomized controlled trial of iACT, a novel mHealth intervention for eating disorders in type 1 diabetes (ED-T1DM). Participants will be 128 T1DM patients between the ages of 16-45 with binge-purge EDs, including threshold and subthreshold bulimia nervosa, binge eating disorder and purging disorder. Participants will be randomized to either iACT or Usual Care, and complete assessments at baseline and every 3 months for 9 months. The primary outcome of interest is glycemic control as assessed by continuous glucose monitoring. Other outcomes include HbA1c, eating disorder symptoms, diabetes self-management and diabetes distress. In addition to examining clinical outcomes, this study tests biobehavioral mechanisms of change and predictors of treatment response. Process of change assessments focus on flexible responding to pathology-relevant stimuli and early improvement in glycemic control affecting executive function. The primary site is Duke University Medical Center. The Miriam Hospital is a secondary site.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 1 Diabetes, Eating Disorders
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
128 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
iACT Experimental Intervention
Arm Type
Experimental
Arm Title
Usual Care
Arm Type
Active Comparator
Intervention Type
Behavioral
Intervention Name(s)
iACT
Intervention Description
Treatment is based on Acceptance and Commitment Therapy (ACT), a contemporary cognitive behavioral therapy (CBT) that improves human functioning and adaptability by increasing psychological flexibility. Individual therapy sessions are paired with mobile phone delivered interventions.
Intervention Type
Other
Intervention Name(s)
Usual Care
Intervention Description
Usual care for problems in Type 1 diabetes management
Primary Outcome Measure Information:
Title
Change in glycemic control as indexed by continuous glucose monitoring (CGM)
Description
CGM indices of time in range, frequency of Level 1 and 2 hyperglycemia and blood glucose variability
Time Frame
baseline, 6 weeks, 12 weeks, 36 weeks
Title
Change in glycemic control as indexed by hemoglobin A1c (HbA1c)
Description
Glycated hemoglobin (percentage of red blood cells that are glycated providing an estimate of average blood glucose over 3 months)
Time Frame
baseline, 12 weeks, 24 weeks, 36 weeks
Title
Change in eating disorder symptoms as indexed by the Eating Disorder Examination Global score
Description
Severity of eating and body image concerns, frequency of engagement in maladaptive eating and weight control behaviors. Global scores range from 0-6, with higher scores indicating greater symptom severity (worse outcome).
Time Frame
baseline, 12 weeks, 36 weeks
Title
Change in eating disorder symptoms as indexed by the Diabetes Eating Problems Survey
Description
Severity of eating and body image concerns, frequency of engagement in maladaptive eating and weight control behaviors, specifically in the context of diabetes. Scores range from 0-80, with higher scores indicating greater symptom severity (worse outcome).
Time Frame
baseline, 12 weeks, 24 weeks, 36 weeks
Title
Change in diabetes self-management as indexed by the Diabetes Self-Management Questionnaire
Description
Engagement in activities necessary to manage diabetes, including checking blood sugar and administering insulin. Scores range from 0-10 with higher scores indicating better self-management.
Time Frame
baseline, 12 weeks, 24 weeks, 36 weeks
Title
Acceptability as measured by meeting the recruitment target for the study
Description
recruitment of n=128
Time Frame
36 months from start of enrollment
Title
Feasibility as measured by participant attrition less than 20%
Description
Less than n=26 individuals dropping out of treatment prematurely
Time Frame
39 months from start of enrollment
Secondary Outcome Measure Information:
Title
Change in diabetes distress as indexed by the Type 1 - Diabetes Distress Scale
Description
Feelings of stress or overwhelm with the burden of living with diabetes and diabetes management. Scores range from 1-6, with higher scores indicating greater distress (worse outcome)
Time Frame
baseline, 12 weeks, 24 weeks, 36 weeks
Title
Change in NIH PROMIS Scale - Depression
Description
8 items assessing depressive affect, scored 1-5 and t-score normed (mean of 50, standard deviation of 10). Higher scores indicating greater symptoms (worse outcome).
Time Frame
baseline, 12 weeks, 36 weeks
Title
Change in NIH PROMIS Scale - Anxiety
Description
8 items assessing anxious affect, scored 1-5 and t-score normed (mean of 50, standard deviation of 10). Higher scores indicating greater symptoms (worse outcome).
Time Frame
baseline, 12 weeks, 36 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
16 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
16-50 years of age
Diagnosis of Type 1 diabetes
Eating disorder characterized by binge eating and/or problematic weight control behaviors, including withholding insulin (Bulimia Nervosa, Binge Eating and Purging Disorder spectrum diagnoses)
Independently manages diabetes (not reliant on a caregiver)
Exclusion Criteria:
Current suicidal ideation or self-harming behavior
Diagnosis of Avoidant Restrictive Food Intake Disorder or Anorexia Nervosa spectrum diagnoses
Hypoglycemic unawareness as assessed by the Gold Method
Current substance abuse disorder or current or past psychotic disorder
NonEnglish speaking
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Dottie R Mayo, BA
Phone
(919) 668-1935
Email
drm72@duke.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Rhonda Merwin, PhD
Phone
(919) 681-7231
Email
rhonda.merwin@duke.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Rhonda Merwin, PhD
Organizational Affiliation
Duke University faculty
Official's Role
Principal Investigator
Facility Information:
Facility Name
Duke University
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27705
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dottie R Mayo, BA
Phone
919-668-1935
Email
dorothy.mayo@duke.edu
First Name & Middle Initial & Last Name & Degree
Rhonda M Merwin, Ph.D.
Facility Name
Brown University
City
Providence
State/Province
Rhode Island
ZIP/Postal Code
02903
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Erica F Robichaud, LCSW
Phone
401-793-8957
Email
eferguson@lifespan.org
First Name & Middle Initial & Last Name & Degree
Jason Lillis, Ph.D.
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
iACT for Eating Disorders in Type 1 Diabetes
We'll reach out to this number within 24 hrs